Traws Pharma, Inc. (TRAW) AI Stock Analysis

Traws Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing small molecule oral therapies for respiratory viral diseases and oncological conditions. Key pipeline candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor targeting COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor for pandemic influenza. In oncology, the firm is developing narazaciclib, a Phase 1/2 clinical candidate targeting CDK4/6 kinases in cancer patients, including endometrial cancer, as well as oral rigosertib for various cancers. Founded in 1998 and based in Newtown, Pennsylvania, the firm was formerly known as Onconova Therapeutics, Inc. before rebranding in April 2024.

Revenue held at $226,000 annually from FY2021 through FY2024 before increasing 1134.5% to $2.8M in FY2025. This drove net income to $9.2M and EPS to $1.04 in FY2025, up from net income of -$54.7M and EPS of -$108.96 in FY2024. Operating margins moved from -21835.4% in FY2024 to -640.7% in FY2025. However, trailing twelve month revenue stands at $0, with quarterly revenue falling 100.0% year-over-year in the latest quarter ended June 30, 2026. For that period, trailing twelve month EPS was -$1.71, with return on equity at -433.4%.

As of June 30, 2026, Traws Pharma held $5.0M in cash and short-term investments, total assets of $11.5M, and shareholders' equity of $1.7M. The company's current ratio stood at 0.93. Operating cash flow was -$18.2M in FY2025, resulting in free cash flow of -$20.8M. Cash deployment during FY2025 included $2.6M in capital expenditures and $2.4M allocated to share buybacks. The company's share count expanded 1726.4% over five years.

Traws Pharma trades at a price-to-sales multiple of 3.0x, below the median of its US-listed Healthcare peers of 4.1x. Its enterprise value to EBITDA is 0.3x, compared to the peer median of 12.0x, while its price-to-book ratio is 4.5x. Over the past year, the stock fell 86.2%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year period, the stock declined 99.6% compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 2 Hold ratings, with 0 Buy and 0 Sell ratings. The mean price target is $1.00, representing a 170.8% premium to the last close of $0.37 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$1.33. For the following fiscal year, analysts forecast revenue of $0 and an EPS of -$1.88. The company has beaten EPS expectations in 3 of the last 4 quarters, with its next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Traws Pharma, Inc. (TRAW). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TRAW income statement, TRAW balance sheet, TRAW key metrics, TRAW analyst forecast, TRAW chart. See the TRAW stock overview for the latest quote and news.